NeuroOne Medical Technologies (US:NMTC)2024-12-17 14:42Financial Data and Key Metrics Changes - Product revenue for Q4 2024 was $1.3 million, a decrease from $1.7 million in Q4 2023 due to the cancellation of a purchase order to transition manufacturing to the new OneRF product line [17] - Product revenue for the full fiscal year 2024 increased by 77% to $3.5 million compared to $2 million in fiscal year 2023 [18] - Total operating expenses decreased by 12% to $3 million in Q4 2024 compared to $3.4 million in Q4 2023 [18] - The net loss for Q4 2024 was $3.3 million, compared to a net loss of $3.1 million in Q4 2023 [19] - The company expects product revenue for fiscal year 2025 to range between $8 million and $10 million, representing an increase of 132% to 190% compared to fiscal year 2024 [21] Business Line Data and Key Metrics Changes - The OneRF Ablation System is the first and only FDA cleared system for both reporting electrical activity and ablation of nervous tissue [5] - The company has completed OneRF Ablation procedures on 12 patients, with all patients either seizure-free or experiencing significant reductions in seizure occurrences [8] - 24 epilepsy centers have requested proposals to acquire the technology, doubling from the previous quarter [8] Market Data and Key Metrics Changes - The new ICD-10-PCS code for the OneRF ablation procedure became effective on October 1, 2024, facilitating accurate data collection and reimbursement claims [9] Company Strategy and Development Direction - The company aims to pursue additional applications for RF Ablation outside of the brain, targeting conditions like trigeminal neuralgia [10] - The OneRF Ablation System is seen as a platform technology for multiple indications, providing competitive differentiation [11] - The company is exploring partnerships for its spinal cord stimulation and drug delivery technologies [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in driving revenue growth and margin improvement in 2025, supported by the recent partnership with Zimmer Biomet [6][24] - The company is optimistic about the commercialization of the trigeminal nerve indication potentially in calendar year 2025 [24] Other Important Information - The company completed a $2.65 million private placement and had cash and cash equivalents of $1.5 million as of September 30, 2024 [20] - The company had no debt outstanding as of September 30, 2024 [20] Summary of Q&A Session - No specific questions or answers were provided in the content regarding the Q&A session.